Publications in collaboration with researchers from Oslo University Hospital (14)

2024

  1. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266

2023

  1. Social media ambassadors and collaboration with OncoAlert: A European Network of Young Gynae Oncologists study of comparative Twitter analysis of #ESGO2021 and #ESGO2022

    International Journal of Gynecological Cancer, Vol. 33, Núm. 6, pp. 964-970

2022

  1. Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study

    Gynecologic Oncology, Vol. 166, Núm. 1, pp. 36-43

  2. Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis

    Gynecologic Oncology, Vol. 164, Núm. 3, pp. 498-504

2020

  1. COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers

    International Journal of Gynecological Cancer

  2. COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers

    Obstetrical and Gynecological Survey

2019

  1. Author Correction: ‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development (Nature Immunology, (2019), 20, 11, (1409-1413), 10.1038/s41590-019-0503-1)

    Nature Immunology

  2. Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer

    Gynecologic Oncology, Vol. 152, Núm. 1, pp. 53-60

  3. ‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development

    Nature Immunology

2017

  1. European society of Gynaecological Oncology (ESGO) guidelines for ovarian cancer surgery

    International Journal of Gynecological Cancer, Vol. 27, Núm. 7, pp. 1534-1542

  2. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

    Obstetrical and Gynecological Survey

  3. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial

    Gynecologic Oncology, Vol. 144, Núm. 1, pp. 65-71

2016

  1. European society of gynaecologic oncology quality indicators for advanced ovarian cancer surgery

    International Journal of Gynecological Cancer, Vol. 26, Núm. 7, pp. 1354-1363

  2. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer

    New England Journal of Medicine, Vol. 375, Núm. 22, pp. 2154-2164